eXoZymes receives $2M NIH Phase IIB SBIR grant for cannabinoid analog drug discovery

EXOZYMES INC.

NIH NIGMS Phase IIB SBIR grant of $2,028,518 to support development of rare cannabinoids and engineered analogs.
Work on two-year grant begins July 1, 2026; total non-dilutive funding now ~$19.7M.
Grant adds a second biosolution to eXoZymes' pipeline after NCT, targeting pharmaceutical partnerships.
U.S. minor cannabinoids market forecast to grow from $11.5B (2023) to $33.3B (2030) at ~15% CAGR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.